#United States #San Francisco #Securities Class Action #FTC #Hims & Hers

Hims & Hers Health Faces Legal Troubles

Hims & Hers Health, Inc. (NYSE: HIMS) is currently grappling with a securities class action lawsuit initiated by disgruntled investors. This development comes on the heels of a severe complaint from the FTC that details accusations of serious misconduct in the company’s business practices. The implications of these allegations have already had a detrimental effect on the company’s stock price, demonstrating the potential financial consequences of such legal challenges.

Background of the Lawsuit

On July 29, 2026, the Federal Trade Commission (FTC) filed a complaint against Hims, alleging that the company engaged in deceptive marketing practices regarding how personal and health information was handled. The complaint alleged three major points:
1. Unauthorized Sharing of Health Data: Hims reportedly shared sensitive health information of its users with third-party advertising platforms like Meta and Snap. This was done without adequate consent and contrary to their claims about strict privacy protections.
2. Subscription and Billing Issues: The complaint accused Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA). It alleged that consumers were charged for prescriptions almost immediately after completing an intake form, even before having a consultation with a medical provider. This practice raised concerns about informed consent due to the hidden cancellation options that made it difficult for consumers to terminate their subscriptions.
3. Impact of Regulatory Scrutiny: The lawsuit also noted that due to these alleged infractions, Hims may be subjected to increased regulatory scrutiny, resulting in additional fees and penalties that could affect its financial standing.

Stock Price Crash

The stock market reacted swiftly to the FTC's allegations. Following the release of the complaint, shares of Hims dropped significantly by $4.32, equating to a 14.7% decrease. This abrupt decline erased nearly $970 million from the company's market capitalization within a single day. Investors have expressed concerns about whether they were misled regarding the integrity of Hims' business operations, adding to the urgency for a thorough investigation.

Company Response and Investigation

Hagens Berman, the law firm leading the investigation on behalf of investors, has invited those who have suffered financial losses due to Hims' practices to come forward. According to Reed Kathrein, a partner at Hagens Berman, the focal point of the investigation will be whether Hims intentionally misrepresented its business practices and constituted sufficient internal controls to protect consumers' private data.

Those with inside information about Hims are encouraged to review their options for cooperating with the ongoing investigation and even consider whistleblowing. There are protections in place, including potential financial rewards for whistleblowers who provide valuable information related to the allegations against the company.

Conclusion

The ongoing legal action against Hims & Hers illustrates the significant risks that can arise when companies fail to safeguard their customers' information and uphold their commitments to transparency. The outcome of this case may not only determine the future of Hims but also serve as a cautionary tale for other companies in the health tech space. Investors and customers alike will be watching closely as the legal proceedings unfold.